LYON, France, April 22, 2021 -- EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today the launch of a follow-on public offering of its American Depositary Shares, or ADSs, each representing one ordinary share of the Company.
Ablatherm FDA Study in Triangle Business Journal EDAP's Ablatherm-HIFU FDA clinical study was recently featured in the Triangle Business Journal. The article is viewable online at http://triangle.bizjournals.com/triangle/stories/2006/07/17/focus4.html . A patient treated at Duke University
Ablatherm Peer Reviewed Data Featured on Top Urology Reference Site EDAP and Ablatherm-HIFU were again featured in an email distributed by UroToday.com to more than 14,000 urologists advising them of the site's HIFU Resource Center. Urotoday.com, located at http://www.urotoday.com , is one of the
Ablatherm-HIFU experience highlighted by UK Prostate Cancer Charity The Prostate Cancer Charity , the largest and most comprehensive charity in the UK focused on prostate cancer, recently included a 4-page detailed overview of HIFU treatment for localized prostate cancer in its widely distributed
Ablatherm-HIFU featured in UroToday.com Electronic Newsletter EDAP and Ablatherm-HIFU were recently featured in an email distributed by UroToday.com to more than 10,000 urologists advising them of the site's HIFU Resource Center. Urotoday.com, located at http://www.urotoday.com , is one of the top
Ablatherm-HIFU featured on Euronews Video Broadcast EDAP and the Ablatherm-HIFU were featured on June 24 in a Euronews video segment. Euronews is a video broadcast network covering more than 120 million households in Europe, Canada and Southeast Asia. The video is linked here for your viewing with
